Simplifying Influenza Vaccination During Pandemics: Sublingual Priming and Intramuscular Boosting of Immune Responses with Heterologous Whole Inactivated Influenza Vaccine
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The best approach to control the spread of influenza virus during a pandemic is vaccination. Yet, an appropriate vaccine is not available early in the pandemic since vaccine production is time consuming. For influenza strains with a high pandemic potential like H5N1, stockpiling of vaccines has been considered but is hampered by rapid antigenic drift of the virus. It has, however, been shown that immunization with a given H5N1 strain can prime the immune system for a later booster with a drifted variant. Here, we investigated whether whole inactivated virus (WIV) vaccine can be processed to tablets suitable for sublingual (s.l.) use and whether s.l. vaccine administration can prime the immune system for a later intramuscular (i.m.) boost with a heterologous vaccine. In vitro results demonstrate that freeze-drying and tableting of WIV did not affect the integrity of the viral proteins or the hemagglutinating properties of the viral particles. Immunization experiments revealed that s.l. priming with WIV (prepared from the H5N1 vaccine strain NIBRG-14) 4 weeks prior to i.m. booster immunization with the same virus strongly enhanced hemagglutination-inhibition (HI) titers against NIBRG-14 and the drifted variant NIBRG-23. Moreover, s.l. (and i.m.) immunization with NIBRG-14 also primed for a subsequent heterologous i.m. booster immunization with NIBRG-23 vaccine. In addition to HI serum antibodies, s.l. priming enhanced lung and nose IgA responses, while i.m. priming enhanced lung IgA but not nose IgA levels. Our results identify s.l. vaccination as a user-friendly method to prime for influenza-specific immune responses toward homologous and drifted variants.
- Wyman O. Influenza vaccine strategies for broad global access key findings and project methodology. 2007.
- Jennings, LC, Monto, AS, Chan, PKS, Szucs, TD, Nicholson, KG, Royal, L (2008) Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 8: pp. 650-8 CrossRef
- Longini, IM, Nizam, A, Xu, S, Ungchusak, K, Hanshaoworakul, W, Cummings, DAT (2005) Containing pandemic influenza at the source. Science 309: pp. 1083-7 CrossRef
- Luykx, DM, Casteleijn, MG, Jiskoot, W, Westdijk, J, Jongen, PMJM (2004) Physicochemical studies on the stability of influenza haemagglutinin in vaccine bulk material. Eur J Pharm Sci 23: pp. 65-75 CrossRef
- Coenen, F, Tolboom, JTBM, Frijlink, HW (2006) Stability of influenza sub-unit vaccine: does a couple of days outside the refrigerator matter?. Vaccine 24: pp. 525-31 CrossRef
- Carrat, F, Flahault, A (2007) Influenza vaccine: the challenge of antigenic drift. Vaccine 25: pp. 6852-62 CrossRef
- Wang, H, Feng, Z, Shu, Y, Yu, H, Zhou, L, Zu, R (2008) Probable limited person-to-person transmission of highly pathogenic avian influenza A H5N1. virus in China. Lancet 371: pp. 1427-34 CrossRef
- Ungchusak, K, Auewarakul, P (2005) Probable person-to-person transmission of avian influenza A H5N1. N Engl J Med 352: pp. 333-40 CrossRef
- Imai, M, Herfst, S, Sorrell, EM, Schrauwen, EJ, Linster, M, De Graaf, M (2013) Transmission of influenza A/H5N1 viruses in mammals. Virus Res 178: pp. 15-20 CrossRef
- Russell, CA, Fonville, JM, Brown, AEX, Burke, DF, Smith, DL, James, SL (2012) The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science 336: pp. 1541-7 CrossRef
- Herfst, S, Schrauwen, EJ, Linster, M, Chutinimitkul, S, Wit, E, Munster, VJ (2012) Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336: pp. 1534-41 CrossRef
- Stephenson, I, Nicholson, KG, Hoschler, K, Zambon, MC, Hancock, K, DeVos, J (2008) Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 359: pp. 1631-3 CrossRef
- Baz, M, Luke, CJ, Cheng, X, Jin, H, Subbarao, K (2013) H5N1 vaccines in humans. Virus Res 178: pp. 78-98 CrossRef
- WHO. Updated unified nomenclature system for the highly pathogenic H5N1 avian influenza viruses.2011.
- Continued evolution of highly pathogenic avian influenza A H5N1: updated nomenclature. Influenza Other Respir Viruses 6: pp. 1-5 CrossRef
- WHO. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines 2006; 81:328–30.
- Belshe, RB, Frey, SE, Graham, I, Mulligan, MJ, Edupuganti, S, Jackson, L (2011) Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis 203: pp. 666-73 CrossRef
- Garmise, RJ, Staats, HF, Hickey, AJ (2007) Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. AAPS PharmSciTech 8: pp. E81 CrossRef
- Amorij, J-P, Meulenaar, J, Hinrichs, WLJ, Stegmann, T, Huckriede, A, Coenen, F (2007) Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine 25: pp. 6447-57 CrossRef
- Geeraedts, F, Saluja, V, Veer, W, Amorij, JP, Frijlink, HW, Wilschut, J (2010) Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures. AAPS J 12: pp. 215-22 CrossRef
- Audouy, SAL, Schaaf, G, Hinrichs, WLJ, Frijlink, HW, Wilschut, J, Huckriede, A (2011) Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization. Vaccine 29: pp. 1-8 CrossRef
- Murugappan, S, Patil, HP, Kanojia, G, Veer, W, Meijerhof, T, Frijlink, HW (2013) Physical and immunogenic stability of spray freeze-dried influenza vaccine powder for pulmonary delivery: comparison of inulin, dextran, or a mixture of dextran and trehalose as protectants. Eur J Pharm Biopharm 85: pp. 716-25 CrossRef
- Boudreault, A, Pavilanis, V (1972) Oral immunization against influenza virus. Arch Gesamte Virusforsch 38: pp. 177-182 CrossRef
- Shim, B-S, Choi, Y, Cheon, IS, Song, MK (2013) Sublingual delivery of vaccines for the induction of mucosal immunity. Immune Netw 13: pp. 81-5 CrossRef
- Pedersen, G, Cox, R (2012) The mucosal vaccine quandary: intranasal vs. sublingual immunization against influenza. Hum Vaccin Immunother 8: pp. 689-93 CrossRef
- Kweon M-NN. Sublingual mucosa: a new vaccination route for systemic and mucosal immunity. Cytokine 2011:10–4.
- Pedersen GK, Ebensen T, Gjeraker IH, Svindland S, Bredholt G, Guzmán CA, et al. Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLoS One 2011;6: doi:10.1371/journal.pone.0026973.
- Shim B-SS, Choi YK, Yun C-HH, Lee E-GG, Jeon YS, Park S-MM, et al. Sublingual Immunization with M2-Based Vaccine Induces Broad Protective Immunity against Influenza. PLoS One 2011;6. doi:10.1371/journal.pone.0027953.
- Song, JH, Nguyen, HH, Cuburu, N, Horimoto, T, Ko, SY, Park, SH (2008) Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci U S A 105: pp. 1644-9 CrossRef
- Amorij, J-P, Hinrichs, WL, Frijlink, HW, Wilschut, JC, Huckriede, A (2010) Needle-free influenza vaccination. Lancet Infect Dis 10: pp. 699-711 CrossRef
- Bensadoun, A, Weinstein, D (1976) Assay of proteins in the presence of interfering materials. Anal Biochem 70: pp. 241-50 CrossRef
- Rawas-Qalaji MM, Estelle F, Simons R, Simons KJ, Simons FE. Fast-disintegrating sublingual tablets: effect of epinephrine load on tablet characteristics. AAPS PharmSciTech 2006;7: doi:10.1208/pt070241.
- Blum, H, Beier, H, Gross, HJ (1987) Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels. Electrophoresis 8: pp. 93-9 CrossRef
- Amorij, J-P, Saluja, V, Petersen, AH, Hinrichs, WLJ, Huckriede, A, Frijlink, HW (2007) Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. Vaccine 25: pp. 8707-17 CrossRef
- Jong, JC, Palache, AM, Beyer, WEP, Rimmelzwaan, GF, Boon, ACM, Osterhaus, ADME (2003) Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 115: pp. 63-73
- Hobson, D, Curry, RL, Beare, AS, Ward-Gardner, A (1972) The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg Lond 70: pp. 767-77 CrossRef
- FDA. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated Influenza vaccines 2013.
- Borde, A, Ekman, A, Holmgren, J, Larsson, A (2012) Effect of protein release rates from tablet formulations on the immune response after sublingual immunization. Eur J Pharm Sci 47: pp. 695-700 CrossRef
- Baz M, Luke CJ, Cheng X, Jin H, Subbarao K. H5N1 vaccines in humans. Virus Res 2013:1–21.
- Belshe, RB, Frey, SE, Graham, I, Mulligan, MJ, Edupuganti, S, Jackson, LA (2011) Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis 203: pp. 666-73 CrossRef
- Wu, J, Fang, H-H, Chen, J-T, Zhou, J-C, Feng, Z-J, Li, C-G (2009) Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza H5N1. vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis 48: pp. 1087-95 CrossRef
- Goji, NA, Nolan, C, Hill, H, Wolff, M, Noah, DL, Williams, TB (2008) Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 H5N1. Vaccine after priming with an antigenic variant. J Infect Dis 198: pp. 635-41 CrossRef
- Vemula S V, Ahi YS, Swaim A-M, Katz JM, Donis R, Sambhara S, et al. Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness. PLoS One 2013;8: doi:10.1371/journal.pone.0062496.
- Renegar, KB, Small, PA, Boykins, LG, Wright, PF (2004) Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173: pp. 1978-86
- Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, Pool J, et al. Superior immunogenicity of inactivated whole virus H5N1 Influenza vaccine is primarily controlled by toll-like receptor signalling.PLoS Pathog 2008;8: doi:10.1371/journal.ppat.1000138.
- Cuburu, N, Kweon, M-N, Song, J-H, Hervouet, C, Luci, C, Sun, J-B (2007) Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 25: pp. 8598-610 CrossRef
- Rudnic EM, Schwartz JB. Remington: the science and practice of pharmacy, oral solid dosage forms.Remington’s pharmaceutical sciences. 21st ed. Lippincott Williams & Wilkins; 2006.
- Simplifying Influenza Vaccination During Pandemics: Sublingual Priming and Intramuscular Boosting of Immune Responses with Heterologous Whole Inactivated Influenza Vaccine
The AAPS Journal
Volume 16, Issue 2 , pp 342-349
- Cover Date
- Online ISSN
- Springer US
- Additional Links
- bird flu
- mucosal vaccine
- sublingual vaccine tablet
- whole inactivated virus
- Industry Sectors
- Author Affiliations
- 1. Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands
- 2. Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands